Synthetic oligonucleotides: useful molecules? A review

Area of Science:

• Molecular Biology
• Gene Regulation
• Biotechnology

Background:

• Specific gene inhibition in mammals is achievable using antisense oligonucleotides (AS ODNs) and ribozymes.
• These molecular tools have significantly advanced the understanding of cellular mechanisms, including cancer development.
• Recent therapeutic applications for AS ODNs and ribozymes include diseases like AIDS and cancer.

Purpose of the Study:

• To review the application of gene inhibition strategies (AS ODNs and ribozymes) in understanding cellular mechanisms and disease.
• To explore the therapeutic potential of AS ODNs and ribozymes, particularly when combined with gene transfer technology.
• To highlight the current challenges hindering the routine clinical use of these gene inhibition methods.

Main Methods:

• Utilizing antisense oligonucleotides (AS ODNs) for specific messenger RNA (mRNA) targeting and degradation.
• Employing ribozymes as catalytic RNA molecules to cleave specific RNA targets.
• Integrating AS ODN or ribozyme delivery with gene transfer technologies (adenoviral, retroviral vectors) for intracellular expression.

Main Results:

• AS ODNs and ribozymes have proven effective in specific mammalian gene inhibition.
• These strategies have elucidated key molecular pathways involved in diseases like cancer.
• Therapeutic trials combining gene transfer with AS ODNs or ribozymes show promise but require further development.

Conclusions:

• Antisense oligonucleotides and ribozymes are powerful tools for gene function studies and potential therapeutics.
• The combination of gene transfer technology with AS ODNs or ribozymes offers a novel therapeutic approach.
• Significant hurdles remain in optimizing delivery and efficacy for routine clinical implementation of these gene inhibition strategies.